clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT04285567 |
P6099 | clinical trial phase | phase III clinical trial | Q42824827 |
P17 | country | Spain | Q29 |
Italy | Q38 | ||
United States of America | Q30 | ||
Australia | Q408 | ||
P582 | end time | 2023-04-08 | |
P1050 | medical condition | leukemia | Q29496 |
P2899 | minimum age | 18 | |
P1132 | number of participants | 165 | |
P4844 | research intervention | fludarabine phosphate | Q185916 |
bendamustine hydrochloride | Q27272066 | ||
obinutuzumab | Q389496 | ||
(RS)-cyclophosphamide | Q408524 | ||
rituximab | Q412323 | ||
vidarabine | Q415107 | ||
venetoclax | Q23671272 | ||
P1813 | short name | CRISTALLO | |
P859 | sponsor | Hoffmann-La Roche | Q212646 |
P580 | start time | 2020-02-28 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare The Efficacy and Safety of A Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine and Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) or TP53 Mutation |